Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 63 of 114

  1. MK3475-054

    Merck Sharp and Dohme

    Stage III melanoma (AJCC R0) with histologically confirmed cutaneous melanoma metastatic to lymph node, classified as (AJCC, 2010): Stage IIIA with metastasis > 1 mm; any Stage IIIB or IIIC (no in-transit metastases)

    phase 3 small molecule active

    1 trial

  2. MK3475-859

    Merck Sharp and Dohme

    Gastric and gastric esophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  3. MK3475-B15

    Merck Sharp and Dohme

    Muscle Invasive Bladder Cancer

    phase 3 small molecule active

    1 trial

  4. ML42502

    Hoffmann-La Roche

    HER2-POSITIVE EARLY BREAST CANCER

    phase 3 small molecule active

    1 trial

  5. MLN0002-3024

    Takeda

    Moderately to severely active Ulcerative Colitis (UC)

    phase 3 small molecule active

    1 trial

  6. MLN0002-3025

    Takeda

    Moderately to severely active Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  7. MLN0002-3029

    Takeda

    Active Ulcerative Colitis (UC) or Crohn's disease (CD)

    phase 3 small molecule active

    1 trial

  8. MLS-101-301

    Mineralys Therapeutics

    Uncontrolled and Resistant Hypertension

    phase 3 small molecule active

    1 trial

  9. MLS-101-901

    Mineralys Therapeutics

    Hypertension

    phase 3 small molecule active

    1 trial

  10. MMX Mesalamine/Mesalazine (Low Dose)

    Takeda

    Ulcerative Colitis

    phase 3 small molecule completed

    1 trial

  11. MN39158

    Hoffmann-La Roche

    Multiple sclerosis (MS)

    phase 3 small molecule active

    1 trial

  12. MN39159

    Hoffmann-La Roche

    Progressive multiple sclerosis (PMS)

    phase 3 small molecule active

    1 trial

  13. MN45053

    Hoffmann-La Roche

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  14. MN45053

    Hoffmann-La Roche

    Neurological Disease

    phase 3 small molecule active

    1 trial

  15. MO29406

    Hoffmann-La Roche

    Solid Malignant Tumors

    phase 3 small molecule active

    1 trial

  16. MO29872

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  17. MO40598

    Hoffmann-La Roche

    Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  18. MO41552

    Hoffmann-La Roche

    Non-small cell lung cancer with ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) gene rearrangements

    phase 3 small molecule active

    1 trial

  19. MO41787

    Hoffmann-La Roche

    Hemophilia A

    phase 3 small molecule active

    1 trial

  20. MO43110

    Hoffmann-La Roche

    Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer

    phase 3 small molecule active

    1 trial

  21. MO43110

    Hoffmann-La Roche

    Early Breast Cancer

    phase 3 small molecule completed

    1 trial

  22. MOG001

    Lacuna Pharma Pty Ltd

    Myelin oligodendrocyte glycoprotein antibody-associated disease (MOG-AD)

    phase 3 small molecule active

    1 trial

  23. MOM-M281-006

    Janssen-Cilag International N.V.

    Warm Autoimmune Hemolytic Anemia

    phase 3 small molecule active

    1 trial

  24. MOR208C310

    Incyte

    Newly-diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL)

    phase 3 small molecule active

    1 trial

  25. MORE

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use

    phase 3 other active

    1 trial

  26. MORE and MI and NRT

    BRIGHT MINDS BIOSCIENCES INC.

    Polysubstance Abuse

    phase 3 other active

    1 trial

  27. MOTOR

    Istituto Gentili S.r.l.

    patients scheduled to undergo elective surgical procedures with general anesthesia

    phase 3 small molecule active

    1 trial

  28. MOVIPREP

    Takeda

    Bowel Preparation Prior to Endoscopic, Radiological and Other Examinations as Well as to Surgical Procedures Which Require Empty Bowel.

    phase 3 small molecule completed

    1 trial

  29. MP-424

    Vertex Pharmaceuticals (Australia) Pty.

    Hepatitis C

    phase 3 small molecule completed

    2 trials

  30. MP-424

    Vertex Pharmaceuticals (Australia) Pty.

    Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

  31. MPs

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hematological Diseases

    phase 3 mab active

    1 trial

  32. MR45625

    Hoffmann-La Roche

    Neovascular Age-Related Macular Degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  33. MRI

    United Therapeutics Europe Ltd

    Prostate Neoplasm

    phase 3 other completed

    1 trial

  34. MRX-802

    Lacuna Pharma Pty Ltd

    Cholestatic Pruritus

    phase 3 small molecule active

    1 trial

  35. MS700568_0183

    Merck Sharp and Dohme

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  36. MT-1186

    Tanabe Pharma

    ALS

    phase 3 small molecule terminated

    1 trial

  37. MT-3-01

    Minoryx Therapeutics S.L.

    Cerebral adrenoleukodystrophy (cALD)

    phase 3 small molecule active

    1 trial

  38. MT-5547

    Tanabe Pharma

    Osteoarthritis, Knee / Osteoarthritis, Hip

    phase 3 small molecule completed

    1 trial

  39. MT-7117 Formulation Code C

    Lacuna Pharma Pty Ltd

    Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

    phase 3 small molecule active

    1 trial

  40. MT-7117 Formulation Code C, MT-7117 Placebo

    Lacuna Pharma Pty Ltd

    Erythropoietic Protoporphyria or X-Linked Protoporphyria

    phase 3 small molecule active

    1 trial

  41. MTX

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gestational Trophoblastic Tumor

    phase 3 small molecule active

    1 trial

  42. MTX230-301

    Biodexa Pharmaceuticals Plc

    Familial adenomatous polyposis (FAP)

    phase 3 small molecule active

    1 trial

  43. MW2022-06-22

    MediWound Germany GmbH

    Venous leg ulcer

    phase 3 small molecule active

    1 trial

  44. MYL-1603N-3001

    Mylan Pharma UK

    Major Depression Disorder

    phase 3 small molecule active

    1 trial

  45. MYL-1603N-3002

    Mylan Pharma UK

    Major Depression Disorders

    phase 3 small molecule active

    1 trial

  46. MYOBLOC

    SUPERNUS PHARMACEUTICALS, INC.

    Sialorrhea

    phase 3 small molecule completed

    2 trials

  47. MYOBLOC Low Dose

    SUPERNUS PHARMACEUTICALS, INC.

    Sialorrhea

    phase 3 small molecule terminated

    1 trial

  48. MaaT013

    Lacuna Pharma Pty Ltd

    Treatment of acute graft-versus host disease (aGvHD) to the gastrointestinal (GI) tract of patients who are resistant or intolerant to ruxolitinib.

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.